Biomedical Manufacturing Program, CSIRO, 343 Royal Parade, Parkville, VIC 3052, Australia.
Cancer Therapeutics CRC, Parkville, VIC 3052, Australia.
Acta Crystallogr D Struct Biol. 2020 Sep 1;76(Pt 9):889-898. doi: 10.1107/S2059798320010505. Epub 2020 Aug 17.
Cancer is one of the leading causes of mortality in humans, and recent work has focused on the area of immuno-oncology, in which the immune system is used to specifically target cancerous cells. Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) is an emerging therapeutic target in human cancers owing to its role in degrading cyclic GMP-AMP (cGAMP), an agonist of the stimulator of interferon genes (STING). The available structures of ENPP1 are of the mouse enzyme, and no structures are available with anything other than native nucleotides. Here, the first X-ray crystal structures of the human ENPP1 enzyme in an apo form, with bound nucleotides and with two known inhibitors are presented. The availability of these structures and a robust crystallization system will allow the development of structure-based drug-design campaigns against this attractive cancer therapeutic target.
癌症是导致人类死亡的主要原因之一,最近的研究工作集中在肿瘤免疫学领域,即利用免疫系统特异性靶向癌细胞。由于其在降解环鸟苷酸-腺苷酸(cGAMP)中的作用,外核苷酸焦磷酸酶/磷酸二酯酶 1(ENPP1)成为人类癌症的一个新兴治疗靶点,cGAMP 是干扰素基因刺激物(STING)的激动剂。目前可获得的 ENPP1 结构为鼠酶结构,并且除了天然核苷酸之外,没有其他结构。本研究首次报道了人 ENPP1 酶的apo 形式、结合核苷酸形式以及两种已知抑制剂的 X 射线晶体结构。这些结构的可用性和稳健的结晶系统将允许针对这一有吸引力的癌症治疗靶点开展基于结构的药物设计活动。